BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-266@pharmaconomics
DTSTAMP:20260707T022209Z
DTSTART;VALUE=DATE:20260514
DTEND;VALUE=DATE:20260515
SUMMARY:BFRI Phase 2 — Ameluz
DESCRIPTION:Phase 2 trial results for Ameluz in moderate to severe acne vulgaris (AV) are due May 14\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/266
URL:https://www.pharmaconomics.com/e/266
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BFRI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR